ENDO Data – New Afirma Xpression Atlas Data Advances Genomic Understanding of Medullary Thyroid Cancer - Afirma® Thyroid Molecular Diagnostics

Patient site
VERACYTE SITE
VERACYTE Portal

LATEST NEWS & EVIDENCE
Patient/Physician Stories
Events
Practice Resources
Physician Portal

Take a look at our new Physician Portal today.

Patient site
VERACYTE SITE
VERACYTE Portal

LATEST NEWS & EVIDENCE
Patient/Physician Stories
Events
Practice Resources
Physician Portal

First name *

Last name *

Email *

Institution *

Zip code *

Which tests interest you (select all that apply) *

Afrima Genomic Sequencing Classifier Afirma Xpression Atlas

More about you *

Endocrinologist Endocrine surgeon Head and neck surgeon General surgeon Surgeon Radiologist Pathologist Cytotech Other

Message *

How can we help?

Veracyte representatives are happy to assist you and discuss how to integrate our tests into your practice. Monday-Friday, 5:30AM - 5PM (Pacific Time)

Headquarters

6000 Shoreline Court, Suite 300

South San Francisco, CA 94080

Client services

+1.844.464.5864 Office

+1.650.243.6388 Fax

Support email

support@veracyte.com

References: 1. Data on file. 2. Hu M, et al, JCEM, 2021. 3. Patel KN, et al, JAMA Surg, 2018. 4. Ali SZ, et al, Cancer Cytopathol, 2019. 5. Hao Y, et al, BMC Syst Biol, 2019. 6. Angell TE, et al, Thyroid, 2019. 7. San Martin VT, et al, JCEM 2019. 8. Andrioli M, et al, Endocr Pathol, 2020. 9. Wei S, et al, Cancer Cytopathol, 2019. 10. Harrell RM, et al, Endocr Pract, 2018. 11. Endo M, et al, Thyroid, 2019. 12. Goldner W, et al, Thyroid, 2019. 13. Stack, et al, ATA, 2019

Afirma is available as part of Veracyte’s CLIA-validated laboratory developed test (LDT) service. This test has not been cleared or approved by the FDA.

Contact us today

Call 1.888.923.4762 or email support@veracyte.com

TERMS & CONDITIONS

© 2022 Veracyte, Inc. All rights reserved.

Afirma, Veracyte, the Afirma logo, and the Veracyte logo are registered trademarks of Veracyte.

Cookie Preferences